UBS Group’s Ortho Clinical Diagnostics Holdings plc Ordinary Shares OCDX Stock Holding History

UBS Group’s Portfolio OCDX Stock Details OCDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-426,885	Closed	-$7.97M	–	11677
2022 Q1	$7.97M	Buy	426,885 +162,793	+62%	+$2.93M	﹤0.01%	2123
2021 Q4	$5.65M	Buy	264,092 +19,500	+8%	+$384K	﹤0.01%	2694
2021 Q3	$4.52M	Buy	244,592 +57,987	+31%	+$1.17M	﹤0.01%	2775
2021 Q2	$4M	Sell	186,605 -21,695	-10%	-$441K	﹤0.01%	2919
2021 Q1	$4.02M	Buy	+208,300	New	+$3.67M	﹤0.01%	2850

Other funds holding OCDX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's OCDX Position: Q2 2022 in Review

UBS Group sold out of Ortho Clinical Diagnostics Holdings plc Ordinary Shares (OCDX) in Q2 2022, closing a stake of 426,885 shares — an estimated $7.97M sold.

UBS Group first reported a position in OCDX in Q1 2021 and held it in 5 quarters. The position peaked at $7.97M in Q1 2022. 1 fund tracked by Wall St. Rank holds OCDX as of Q2 2022.

UBS Group reported no remaining Ortho Clinical Diagnostics Holdings plc Ordinary Shares position as of Q2 2022 after selling out during the quarter.
UBS Group sold 426,885 Ortho Clinical Diagnostics Holdings plc Ordinary Shares shares in Q2 2022, an estimated $7.97M.
UBS Group first reported a position in Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q1 2021 and held it in 5 quarters.
UBS Group's Ortho Clinical Diagnostics Holdings plc Ordinary Shares position peaked at $7.97M in Q1 2022.
1 fund tracked by Wall St. Rank held Ortho Clinical Diagnostics Holdings plc Ordinary Shares as of Q2 2022.

Based on UBS Group's 13F filing for Q2 2022, filed 10 Aug 2022.